azacitidine or decitabine

DRUG3 trials

Sponsors

University of Florida, Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine, Seattle Genetics, Inc.

Conditions

Acute Myeloid LeukemiaHypomethylating AgentMyelodysplastic SyndromesMyeloid MalignancyVenetoclaxacute myelogenous leukemia cancer of the blood

Phase 2

Trial of Cladribine and Low-Dose Cytarabine (LoDAC) Alternating With Decitabine vs. Hypomethylating Agents (HMA) Plus Venetoclax as Frontline Therapy for AML or High-Grade MDS in Patients Unfit for Intensive Induction

WithdrawnNCT05766514

University of FloridaAcute Myeloid Leukemia, Myelodysplastic Syndromes

Start: 2025-04-30End: 2030-12-31Updated: 2025-04-22

Hypomethylating Agent and Venetoclax After Allo-HSCT in Patients With High-risk Myeloid Malignancies.

RecruitingNCT05841771

Shanghai General Hospital, Shanghai Jiao Tong University School of MedicineHypomethylating Agent, Myeloid Malignancy, Venetoclax

Start: 2023-01-01End: 2025-12-31Target: 78Updated: 2024-08-09

Phase 3

A randomized, double-blindphase 3 study of vadastuximab talirine (SGN-CD33A)versus placebo in combination with azacitidine or decitabine in the treatment of older patients with newly diagnosed acute myeloid leukemia (AML)

Seattle Genetics, Inc.acute myelogenous leukemia cancer of the blood

Target: 6Updated: 2024-02-28